HENZO KENYA, is a Community Based Organisation Registered in Kenya. It brings together about 1,500 cancer patients for awareness, mutual support and advocacy. Most of the patients (about 80%, are on treatment for Chronic Myeloid Leukemia (CML) and the rest are being treated for Gastro-intestinal stromal tumors (GIST), other types of Leukemias (CLL and Acute Leukemias), Lymphomas and Myelomas. The patients are drawn from all over the country.

Glivec (Imatinib made by Novartis) is made available free of charge to CML and GIST patients through Max Access Solutions (MAS) in partnership with The Nairobi Hospital and The Ministry of Health. This program, initially GIPAP, was the all important first step towards offering any kind of support to Leukemia patients. Henzo Kenya’s strong CML community has therefore helped to mobilise other patients with hematological malignancies, and help them benefit from the various programs in advocacy, support and awareness.

As of now, there are no CLL specific programs. They hope to develop some as they progress.

Their mission is: To create awareness about Hematological malignancies and GIST, provide emotional and social support to members and to advocate for mainstreaming of issues related to these diseases that affect patients, and general public; with a Vision to be the hub of information, psycho social and emotional support for Cancer patients and a key advocate for the same.

The goals and objectives of Henzo are to reduce Cancer mortality and morbidity rate in Kenya.

Click here to visit the website